These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 12413557)

  • 1. The genesis of high-throughput structure-based drug discovery using protein crystallography.
    Kuhn P; Wilson K; Patch MG; Stevens RC
    Curr Opin Chem Biol; 2002 Oct; 6(5):704-10. PubMed ID: 12413557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural biology and drug discovery.
    Scapin G
    Curr Pharm Des; 2006; 12(17):2087-97. PubMed ID: 16796557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent applications of protein crystallography and structure-guided drug design.
    Williams SP; Kuyper LF; Pearce KH
    Curr Opin Chem Biol; 2005 Aug; 9(4):371-80. PubMed ID: 16006182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-throughput crystallization and structure determination in drug discovery.
    Stewart L; Clark R; Behnke C
    Drug Discov Today; 2002 Feb; 7(3):187-96. PubMed ID: 11815235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advantages of crystallographic fragment screening: functional and mechanistic insights from a powerful platform for efficient drug discovery.
    Patel D; Bauman JD; Arnold E
    Prog Biophys Mol Biol; 2014; 116(2-3):92-100. PubMed ID: 25117499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-throughput X-ray crystallography for drug discovery.
    Blundell TL; Patel S
    Curr Opin Pharmacol; 2004 Oct; 4(5):490-6. PubMed ID: 15351354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining 'dry' co-crystallization and in situ diffraction to facilitate ligand screening by X-ray crystallography.
    Gelin M; Delfosse V; Allemand F; Hoh F; Sallaz-Damaz Y; Pirocchi M; Bourguet W; Ferrer JL; Labesse G; Guichou JF
    Acta Crystallogr D Biol Crystallogr; 2015 Aug; 71(Pt 8):1777-87. PubMed ID: 26249358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-throughput crystallography to enhance drug discovery.
    Sharff A; Jhoti H
    Curr Opin Chem Biol; 2003 Jun; 7(3):340-5. PubMed ID: 12826121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practices in Molecular Docking and Structure-Based Virtual Screening.
    Dos Santos RN; Ferreira LG; Andricopulo AD
    Methods Mol Biol; 2018; 1762():31-50. PubMed ID: 29594766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput quantum-mechanics/molecular-mechanics (ONIOM) macromolecular crystallographic refinement with PHENIX/DivCon: the impact of mixed Hamiltonian methods on ligand and protein structure.
    Borbulevych O; Martin RI; Westerhoff LM
    Acta Crystallogr D Struct Biol; 2018 Nov; 74(Pt 11):1063-1077. PubMed ID: 30387765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Automated protein-ligand crystallography for structure-based drug design.
    Mooij WT; Hartshorn MJ; Tickle IJ; Sharff AJ; Verdonk ML; Jhoti H
    ChemMedChem; 2006 Aug; 1(8):827-38. PubMed ID: 16902937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallization to obtain protein-ligand complexes for structure-aided drug design.
    Danley DE
    Acta Crystallogr D Biol Crystallogr; 2006 Jun; 62(Pt 6):569-75. PubMed ID: 16699182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-throughput protein crystallography and drug discovery.
    Tickle I; Sharff A; Vinkovic M; Yon J; Jhoti H
    Chem Soc Rev; 2004 Oct; 33(8):558-65. PubMed ID: 15480479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental free ligand conformations: a missing link in structure-based drug discovery.
    Chiarparin E; Packer MJ; Wilson DM
    Future Med Chem; 2019 Jan; 11(2):79-82. PubMed ID: 30648432
    [No Abstract]   [Full Text] [Related]  

  • 16. Discovering novel ligands for macromolecules using X-ray crystallographic screening.
    Nienaber VL; Richardson PL; Klighofer V; Bouska JJ; Giranda VL; Greer J
    Nat Biotechnol; 2000 Oct; 18(10):1105-8. PubMed ID: 11017052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Counting on Fragment Based Drug Design Approach for Drug Discovery.
    Kashyap A; Singh PK; Silakari O
    Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fragment-based drug discovery and its application to challenging drug targets.
    Price AJ; Howard S; Cons BD
    Essays Biochem; 2017 Nov; 61(5):475-484. PubMed ID: 29118094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. X-ray crystallography over the past decade for novel drug discovery - where are we heading next?
    Zheng H; Handing KB; Zimmerman MD; Shabalin IG; Almo SC; Minor W
    Expert Opin Drug Discov; 2015; 10(9):975-89. PubMed ID: 26177814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. X-ray crystallography as a tool for mechanism-of-action studies and drug discovery.
    Ennifar E
    Curr Pharm Biotechnol; 2013; 14(5):537-50. PubMed ID: 22429136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.